

WHAT IS CLAIMED IS:

1. A nucleic acid-bound polypeptide which is produced by binding a nucleic acid to a polypeptide.

2. The nucleic acid-bound polypeptide as claimed in Claim 1, wherein said nucleic acid is bound to at least one terminus of said polypeptide.

3. The nucleic acid-bound polypeptide as claimed in Claim 1, further comprising a nucleic acid-binding motif through which said nucleic acid is bound to said polypeptide.

4. The nucleic acid-bound polypeptide as claimed in Claim 2, further comprising a nucleic acid-binding motif through which said nucleic acid is bound to at least said one terminus of said polypeptide.

5. The nucleic acid-bound polypeptide as claimed in Claim 3, wherein said polypeptide and said nucleic acid-binding motif are expressed in the form of a fusion polypeptide by genetic engineering.

6. The nucleic acid-bound polypeptide as claimed in Claim 4, wherein said polypeptide and said nucleic acid-binding motif are expressed in the form of a fusion polypeptide by genetic engineering.

7. The nucleic acid-bound polypeptide as claimed in Claim 3, wherein said nucleic acid-binding motif has an amino acid sequence with sequence No. 2 defined in a sequence table attached to the specification of this application.

8. The nucleic acid-bound polypeptide as claimed in Claim 4, wherein said nucleic acid binding motif has an amino acid sequence with sequence No. 2 defined in a sequence table attached to the specification of this application.

9. The nucleic acid-bound polypeptide as claimed in Claim 1, wherein said polypeptide is an antigen to be assayed by an immunoassay.

10. The nucleic acid-bound polypeptide as claimed in Claim 2, wherein said polypeptide is an antigen to be assayed by an immunoassay.

11. The nucleic acid-bound polypeptide as claimed in Claim 3, wherein said polypeptide is an antigen to be assayed by an immunoassay.

12. The nucleic acid-bound polypeptide as claimed in Claim 4, wherein said polypeptide is an antigen to be assayed by an immunoassay.

13. The nucleic acid-bound polypeptide as claimed in Claim 5, wherein said polypeptide is an antigen to be assayed by an immunoassay.

14. The nucleic acid-bound polypeptide as claimed in Claim 6, wherein said polypeptide is an antigen to be assayed by an immunoassay.

15. A method of producing a nucleic acid-bound polypeptide comprising the steps of:

producing a polypeptide by genetic engineering,
binding a nucleic acid to said polypeptide to
produce a nucleic acid-bound polypeptide as a soluble
fraction, and

purifying said nucleic acid-bound polypeptide from
said soluble fraction.

16. The method of producing said nucleic acid-bound polypeptide as claimed in Claim 15, wherein the step of binding said nucleic acid to said polypeptide to produce said nucleic acid-bound polypeptide comprises the steps of:

fusing a gene which codes said polypeptide and a
gene which codes a nucleic acid-binding motif for binding
said nucleic acid to said polypeptide to produce a fusion
gene, and

expressing said fusion gene to produce said nucleic

acid-bound polypeptide via said nucleic acid-binding motif.

Sub C1
17. An immunoassay for assaying an antigen comprising a polypeptide, or an antibody corresponding to said polypeptide, using as an antigen for said immunoassay a nucleic acid-bound polypeptide obtainable by binding a nucleic acid to said polypeptide.

18. The immunoassay as claimed in Claim 17, wherein said nucleic acid is bound to at least one terminus of said polypeptide.

19. The immunoassay as claimed in Claim 17, wherein said nucleic acid-bound polypeptide further comprises a nucleic acid-binding motif through which said nucleic acid is bound to said polypeptide.

20. The immunoassay as claimed in Claim 18, wherein said nucleic acid-bound polypeptide further comprises a nucleic acid binding motif through which said nucleic acid is combined with at least one terminus of said polypeptide.

21. The immunoassay as claimed in Claim 19, wherein said polypeptide and said nucleic acid-binding motif are expressed in the form of a fusion polypeptide by genetic

engineering.

22. The immunoassay as claimed in Claim 20, wherein said polypeptide and said nucleic acid binding motif are expressed in the form of a fusion polypeptide by genetic engineering.

Sub C2
23. The immunoassay as claimed in Claim 19, wherein said nucleic acid-binding motif has an amino acid sequence with sequence No. 2 defined in a sequence table attached to the specification of this application.

24. The immunoassay as claimed in Claim 20, wherein said nucleic acid-binding motif has an amino acid sequence with sequence No. 2 defined in a sequence table attached to the specification of this application.

Sub D2
25. An agglutination immunoassay for assaying an antigen comprising a polypeptide, or an antibody corresponding to said antigen, using as said antigen a nucleic acid-bound polypeptide which is produced by binding a nucleic acid to a polypeptide, and fixing said nucleic acid-bound polypeptide on the surface of particles.

26. The agglutination immunoassay as claimed in Claim 25, wherein said nucleic acid is bound to at least

one terminus of said polypeptide.

27. The agglutination immunoassay as claimed in Claim 25, wherein said nucleic acid-bound polypeptide further comprises a nucleic acid-binding motif through which said nucleic acid is bound to said polypeptide.

28. The agglutination immunoassay as claimed in Claim 26, wherein said nucleic acid-bound polypeptide further comprises a nucleic acid-binding motif through which said nucleic acid is bound to at least one terminus of said polypeptide.

29. The agglutination immunoassay as claimed in Claim 27, wherein said polypeptide and said nucleic acid-binding motif are expressed in the form of a fusion polypeptide by genetic engineering.

30. The agglutination immunoassay as claimed in Claim 28, wherein said polypeptide and said nucleic acid binding motif are expressed in the form of a fusion polypeptide by genetic engineering.

31. The agglutination immunoassay as claimed in Claim 27, wherein said nucleic acid-binding motif has an amino acid sequence with sequence No. 2 defined in a sequence table attached to the specification of this

application.

32. The agglutination immunoassay as claimed in Claim 28, wherein said nucleic acid-binding motif has an amino acid sequence with sequence No. 2 defined in a sequence table attached to the specification of this application.

09306780-050799

Adg
D4